Andrew V. Schally

70.0k total citations · 14 hit papers
1.6k papers, 54.4k citations indexed

About

Andrew V. Schally is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Andrew V. Schally has authored 1.6k papers receiving a total of 54.4k indexed citations (citations by other indexed papers that have themselves been cited), including 715 papers in Endocrinology, Diabetes and Metabolism, 377 papers in Molecular Biology and 307 papers in Reproductive Medicine. Recurrent topics in Andrew V. Schally's work include Growth Hormone and Insulin-like Growth Factors (584 papers), Hypothalamic control of reproductive hormones (219 papers) and Neuroendocrine Tumor Research Advances (184 papers). Andrew V. Schally is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (584 papers), Hypothalamic control of reproductive hormones (219 papers) and Neuroendocrine Tumor Research Advances (184 papers). Andrew V. Schally collaborates with scholars based in United States, Hungary and Germany. Andrew V. Schally's co-authors include Akira Arimura, Abba J. Kastin, Tommie W. Redding, Kate Groot, David H. Coy, Gábor Halmos, Attila Nagy, Károly Szepesházi, József L. Varga and D.H. Coy and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Andrew V. Schally

1.5k papers receiving 50.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

1971 835 citations Akira Arimura, Andrew V. Schally et al. profile →
Gonadotropin-Releasing Hormone: One Polypeptide Regulates Secretion of Luteinizing and Follicle-Stimulating Hormones

1971 522 citations Andrew V. Schally, Akira Arimura et al. profile →
The Regional Distribution of Somatostatin in the Rat Brain

1975 499 citations Akira Arimura, Andrew V. Schally et al. Endocrinology profile →
INHIBITION OF GASTRIN AND GASTRIC-ACID SECRETION BY GROWTH-HORMONE RELEASE-INHIBITING HORMONE

1974 471 citations D.H. Coy, Andrew V. Schally et al. profile →
Isolation and properties of the FSH and LH-releasing hormone

1971 437 citations Andrew V. Schally, Akira Arimura et al. profile →
The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide

1969 408 citations Andrew V. Schally et al. profile →
Hypothalamic Regulatory Hormones

1973 408 citations Andrew V. Schally, Akira Arimura et al. profile →
Somatostatin: Abundance of Immunoreactive Hormone in Rat Stomach and Pancreas

1975 396 citations Akira Arimura, Andrew V. Schally et al. profile →
Radioimmunoassay for GH-Release Inhibiting Hormone

1975 262 citations Andrew V. Schally et al. profile →
EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS

1974 217 citations Andrew V. Schally, D.H. Coy et al. profile →
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion

1976 205 citations Akira Arimura, Andrew V. Schally et al. profile →
IN VITRO BIOASSAY OF CORTICOTROPIN: MODIFICATION AND STATISTICAL TREATMENT

1955 196 citations Andrew V. Schally et al. Endocrinology profile →
Isolation and structure of hypothalamic MSH release-inhibiting hormone

1971 182 citations Andrew V. Schally et al. profile →
THE RELEASE OF CORTICOTROPHIN BY ANTERIOR PITUITARY TISSUE IN VITRO

1955 173 citations Andrew V. Schally et al. profile →

Peers

Countries citing papers authored by Andrew V. Schally

Since Specialization

Citations

This map shows the geographic impact of Andrew V. Schally's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew V. Schally with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew V. Schally more than expected).

Fields of papers citing papers by Andrew V. Schally

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew V. Schally. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew V. Schally. The network helps show where Andrew V. Schally may publish in the future.

Co-authorship network of co-authors of Andrew V. Schally

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew V. Schally. A scholar is included among the top collaborators of Andrew V. Schally based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew V. Schally. Andrew V. Schally is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Growth hormone-releasing hormone receptor (GHRH-R) and its signaling 2025 ·Reviews in Endocrine and Metabolic Disorders ·Gábor Halmos, Zsuzsanna Szabó, Nikoletta Dobos, Éva Juhász, Andrew V. Schally	1
2	Publisher Correction: Growth hormone-releasing hormone and its analogues in health and disease 2024 ·Nature Reviews Endocrinology ·Riccarda Granata, Sheila Leone, Xianyang Zhang, Iacopo Gesmundo, Charlotte Steenblock, Renzhi Cai, Wei Sha, Ezio Ghigo, Joshua M. Hare, Stefan R. Bornstein, Andrew V. Schally	1
3	Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in a Cohort of Hungarian Pediatric Patients with Hematological and Oncological Disorders: A Pilot Study 2024 ·International Journal of Molecular Sciences ·Éva Juhász, Zsuzsanna Szabó, Andrew V. Schally, (unknown), (unknown), (unknown), Balázs Dezsö, Erzsébet Szabó, Gábor Halmos, Csongor Kiss	3
4	Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction 2023 ·American Journal of Physiology-Heart and Circulatory Physiology ·Rosemeire M. Kanashiro‐Takeuchi, Lauro M Takeuchi, Raúl A Dulce, Katarzyna Kaźmierczak, Wayne Balkan, Renzhi Cai, Wei Sha, Andrew V. Schally, Joshua M. Hare	9
5	Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice 2023 ·Proceedings of the National Academy of Sciences ·Marina Boido, Iacopo Gesmundo, (unknown), (unknown), Roberta Schellino, Sheila Leone, Renzhi Cai, Wei Sha, Ezio Ghigo, Andrew V. Schally, Alessandro Vercelli, Riccarda Granata	6
6	Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction 2021 ·Proceedings of the National Academy of Sciences ·Angela C. Rieger, Luiza Bagno, Alessandro G. Salerno, Victoria Florea, Jose Rodriguez, Marcos Rosado, (unknown), Raúl A Dulce, Lauro M Takeuchi, Rosemeire M. Kanashiro‐Takeuchi, Péter Buchwald, Amarylis Wanschel, Wayne Balkan, Ivonne Hernandez Schulman, Andrew V. Schally, Joshua M. Hare	18
7	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 2019 ·Proceedings of the National Academy of Sciences ·(unknown), Iacopo Gesmundo, Valentina Audrito, Nicoletta Vitale, Francesca Silvagno, (unknown), Luisella Righi, Roberta Libener, Chiara Riganti, Paolo Bironzo, Silvia Deaglio, Mauro Papotti, Renzhi Cai, Wei Sha, Ezio Ghigo, Andrew V. Schally, Riccarda Granata	28
8	Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes 2016 ·Proceedings of the National Academy of Sciences ·Maritza J. Romero, Rudolf Lucas, Huijuan Dou, Supriya Sridhar, István Czikora, (unknown), Ferenc G. Rick, Norman L. Block, Subbaramiah Sridhar, David Fulton, Neal L. Weintraub, Zsolt Bagi, Andrew V. Schally	14
9	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer 2014 ·Clinical Cancer Research ·Stephen V. Liu, Denice Tsao‐Wei, Shigang Xiong, Susan Groshen, Tanya B. Dorff, David I. Quinn, Yu‐Chong Tai, Juergen Engel, Debra Hawes, Andrew V. Schally, Jacek Pinski	37
10	Legends in urology. 2013 ·PubMed ·Andrew V. Schally	1
11	An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer 2013 ·OncoTargets and Therapy ·Ferenc G. Rick, (unknown), Andrew V. Schally	34
12	Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice 2010 ·Proceedings of the National Academy of Sciences ·William A. Banks, John E. Morley, Susan A. Farr, Tulin O. Price, Nuran Erçal, Irving Vidaurre, Andrew V. Schally	43
13	Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer 2007 ·International Journal of Oncology ·Célia A. Kanashiro, Andrew V. Schally, Márta Zarándi, (unknown), József Varga	29
14	Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins 2006 ·International Journal of Oncology ·Gunhild Keller, Andrew V. Schally, Attila Nagy, (unknown), Gábor Halmos, J. Engel	22
15	Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. 2003 ·PubMed ·Ana M. Bajo, Andrew V. Schally, Gábor Halmos, Attila Nagy	45
16	Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. 1996 ·Endocrinology ·J. Pinski, Najib Lamharzi, György B. Halmos, Kate Groot, A. Jungwirth, Manuel Vadillo-Buenfil, Sham S. Kakar, Andrew V. Schally	60
17	Recovery of Pituitary‐Gonadal Function in Male Rats after Long‐Term Suppression Induced by a Single Injection of Microcapsules of LH‐RH Antagonist Cetrorelix (SB‐75) 1993 ·Journal of Andrology ·Jacek Pinski, Tetsu Yano, Károly Szepesházi, Kate Groot, Andrew V. Schally	12
18	Effects of an LH-RH analogue in male rats pretreated with oestradiol benzoate 1978 ·Reproduction ·Robert K. Tcholakian, (unknown), A. K. Chowdhury, M. CHOWDHURY, Andrew V. Schally, Alfred A. Steinberger	8
19	Suppression of LH-RH-induced ovulation in hamsters and rats by synthetic analogues of LH-RH 1976 ·Reproduction ·(unknown), D.H. Coy, Esther J. Coy, Akira Arimura, Andrew V. Schally	9
20	ANOVULATORY UTERINE BLEEDING AFTER ADMINISTRATION OF MSH TO WOMEN WITH SECONDARY AMENORRHOEA 1972 ·Reproduction ·Abba J. Kastin, Arturo Zárate, (unknown), (unknown), Kjell Dyster‐Aas, Carlos García Gual, Andrew V. Schally	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

You can learn more about the impact of Andrew V. Schally by visiting their Pantheon page.

Explore authors with similar magnitude of impact